Enveric Biosciences, Inc.
ENVB· Nasdaq
ENVBEnveric Biosciences, Inc.
Filed Nov 14, 2024 · 10-Q · 45 days after period end · 0001493152-24-045859
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$2.08M | -$2.82M | -$2.48M | -$2.71M |
| EPS Diluted | -$43.10 | -$1.30 | -$1.46 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end
